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In order to identify clinically relevant downstream effectors of androgen 
signalling, the androgen-regulated kinome was defined in prostate cancer 
(PCa). Within this study, Choline kinase alpha (CHKA) was identified as an 
androgen receptor chaperone that is both a biomarker of progression and 
a potential therapeutic target for PCa. 
	
	
	
The	 androgen	 receptor	 (AR)	 is	 an	 oncogenic	 transcription	 factor	 implicated	 in	
prostate	cancer	(PCa)	progression.		Resistance	to	androgen	deprivation	therapy	
occurs	 in	 progression	 to	 castration-resistant	 prostate	 cancer1	 (CRPC)	 and	 is	
accompanied	by	resurgence	of	AR	signalling.	Multiple	mechanisms	can	stimulate	
AR	signalling	 in	CRPC	 including	gain-of-function	mutations	 in	 the	AR	signalling	
pathway2,	up-regulation	of	heat	shock	proteins	(HSPs)	that	act	as	chaperones	for	
AR	and	kinases	that	can	potentiate	AR	function3.	 	 	Consistent	with	this	concept,	
targeting	of	HSPs	and	kinases	in	pre-clinical	models	inhibits	AR	function	and	PCa	
tumour	 growth4,5.	 While,	 these	 diverse	 resistance	 mechanisms	 highlight	 the	
reliance	of	PCa	on	AR	signalling,	 there	 is	 a	 critical	need	 to	 identify	 therapeutic	
targets	that	regulate	AR	function	as	well	as	key	downstream	effector	pathways.	
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We	 profiled	 the	 AR-regulated	 kinome	 in	 PCa	 with	 a	 view	 to	 demonstrating	
functionally	 and	 clinically	 important	 signalling	 events	 downstream	 of	 the	 AR.		
We	 showed	 that	 choline	 kinase	 alpha	 (CHKA)	 is	 a	 chaperone	 for	 the	 AR,	
promoting	its	stability	and	function6.		This	is	the	first	report	demonstrating	that	
kinases	 can	 act	 as	 chaperones.	 During	 our	 studies	 we	 also	 identified	 49	
androgen-regulated	kinases,	of	which	25	were	up-	and	24	down-regulated.	We	
confirmed	the	 in vivo	androgen	regulation	of	a	subset	of	these	genes	 in	tumour	
tissue	 from	 chemically	 castrated	 PCa	 patients	 (18/25	 androgen	 up-regulated	
kinase	genes).			
CHKA	was	overexpressed	in	 localised	(primary)	and	metastatic	PCa,	and	
decreased	in	tissues	from	castrated	men.		Protein	levels	of	CHKA	were	correlated	
with	 Gleason	 Grade	 and	 Stage	 and	 CHKA	 was	 an	 independent	 predictor	 of	
biochemical	 recurrence.	 CHKA	 can	 exist	 as	 two	 isoforms	 CHKA2	 and	 CHKA1.	
Interestingly,	the	interaction	of	CHKA2	with	the	AR	decreased	within	5-15	min	of	
androgen	treatment,	consistent	with	 the	 timing	of	AR	release	 from	cytoplasmic	
chaperones	and	its	translocation	to	the	nucleus.	AR	protein	levels	were	reduced	
by	 CHKA	 knockdown	 indicating	 a	 reciprocal	 role	 of	 CHKA	 in	 regulating	 AR	
protein	levels.	A	direct	physical	interaction	was	mapped	between	CHKA2	and	the	
LBD	 of	 AR	 (ARLBD),	 the	 AR	 domain	 that	 interacts	 with	 HSPs.	 In	 a	 protease	
protection	 assay,	 both	 DHT	 and	 CHKA2	 were	 required	 to	 stabilise	 AR.	 In	 line	
with	 this,	 CHKA	 knockdown	 did	 not	 decrease	 the	 levels	 of	 an	 AR	 variant	
(ARv567es)	lacking	the	LBD.	Taken	together,	our	data	show	for	the	first	time	that	
kinases	 can	 function	 as	 protein	 chaperones	 -	 a	 feature	 never	 previously	
attributed	to	any	kinase.	
3 
 
CHKA	inhibition	decreased	the	activity	of	full	 length	AR,	but	failed	to	inhibit	AR	
variants	 lacking	 the	 LBD,	 indicating	 that	 CHKA	 regulates	 AR	 transcriptional	
activity	by	binding	to	ARLBD.	Transcriptome	sequencing	from	CHKA	knockdown	
in	 C4-2	 cells	 found	 a	 highly	 significant	 bi-directional	 overlap	 between	 siCHKA	
and	 androgen-regulated	 genes,	 consistent	 with	 a	 global	 role	 for	 CHKA	 in	 AR	
regulation.	 Pathway	 analysis	 identified	 enrichment	 for	 pathways	 regulating	
protein	 folding	 and	 cellular	protein	 localisation,	 consistent	with	 the	 chaperone	
function	 of	 CHKA.	 These	 analyses	 highlight	 a	 functional	 link	 between	 AR	 and	
CHKA	 signalling,	 indicating	 a	 cooperative	 function	 of	 CHKA	 in	 driving	 the	 AR-
regulated	transcriptome	by	stabilising	AR	protein	levels.		
CHKA	 inhibition	 induced	apoptosis	 in	many	CRPC	cell	 line	models	 in	a	manner	
similar	to	AR	inhibition.	The	growth-promoting	role	of	CHKA	did	not	depend	on	
the	catalytic	activity	of	CHKA	since	the	addition	of	exogenous	phosphocholine	or	
phosphatidylcholine	did	not	 rescue	growth	 inhibition	by	a	CHKA	 inhibitor	 that	
reduced	 AR	 activity,	 AR	 levels	 and	 CHKA	 levels.	 In	 an	 ex vivo	 culture	 assay,	
treatment	of	hormone-naïve	primary	PCa	tissue	with	CHKA	inhibitor	decreased	
AR	expression	in	tumour	epithelia,	while	increasing	levels	of	cleaved	caspase-3,	a	
marker	of	apoptosis.	Migration	and	invasion	phenotypes	were	also	inhibited	by	
CHKA	 knockdown.	 	 Finally,	 PCa	 xenograft	 growth	 was	 inhibited	 using	 an	
inducible	CHKA	knockdown	system.	Collectively,	these	experiments	indicate	that	
CHKA	 inhibition	opposes	 androgen	action	and	 that	 inhibition	of	CHKA	 reduces	
malignant	 phenotypes	 and	 triggers	 apoptosis	 in	 PCa	 cells	 and	 tissue.	 The	 data	
demonstrate	 the	 importance	of	CHKA	 in	PCa	growth	and	 invasion,	highlighting	
the	 potential	 future	 benefits	 of	 inhibitors	 of	 this	 kinase	 in	 the	 clinical	
management	of	PCa.	
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In	 summary,	 CHKA	 can	 act	 as	 a	 chaperone	 that	 regulates	 AR	 signalling,	
elucidating	a	 feed-forward	AR-CHKA	signalling	 loop	 that	 reinforces	AR	activity,	
allowing	CHKA	to	maintain	its	own	expression	in	PCa.	The	chaperone	function	of	
CHKA	confers	a	growth	advantage	on	PCa	by	stabilizing	the	AR	in	addition	to	its	
well-known	 function	 in	 fuelling	 membrane	 production	 through	 the	 Kennedy	
pathway	7	(Figure	1),	suggesting	a	de facto	role	for	CHKA	as	a	rate-limiting	factor	
in	cancer	cell	growth.		
This	discovery	should	accelerate	the	screening	of	potential	CHKA	inhibitors	that	
will	 not	 only	 inhibit	 the	 catalytic	 function	 but	 also	 decrease	 the	 CHKA	protein	
level.	 We	 believe	 our	 work	 will	 direct	 efforts	 in	 the	 treatment	 of	 PCa	 in	
particular,	but	also	for	other	cancers,	by	stimulating	a	systematic	re-evaluation	of	
CHKA	as	a	 therapeutic	 target	 in	cancers	where	 it	 is	overexpressed	and	exhibits	
analogous	effects	on	other	oncogenic	proteins.			
	
Funding		
This	work	was	supported	by	a	Cancer	Research	UK	program	grant	(to	DEN)		
	
Figure 1.	 Classical and non-classical functions of  
CHKA.	Classical	model	 involves	ubiquitination	and	activation	of	AR-dependent	
transcription	that	results	in	up-regulation	of	CHKA,	a	rate	limiting	enzyme	in	the	
Kennedy	 pathway	 (production	 of	 phosphatidylcholine,	 required	 for	 plasma	
membrane	 biogenesis).	 In	 addition	 to	 its	 role	 in	 Kennedy	 pathway,	 CHKA	 can	
also	interact	with	the	AR	in	cytoplasm	and	promotes	its	stability	(non-classical).	
This	could	lead	to	AR	overexpression	and	increased	AR	signalling	which	in	turn	
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may	 allow	 more	 CHKA	 production.	 AR=androgen	 receptor;	 U=ubiquitin;	
CHKA=choline	kinase	alpha.	
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